RAP1GAP2 Human Pre-designed siRNA Set A

Cat. No.: R1488059

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Panoramica

RAP1GAP2 Human Pre-designed siRNA Set A contains three designed siRNAs for RAP1GAP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components RAP1GAP2 siRNA-1: 5 nmol (HPLC) RAP1GAP2 siRNA-2: 5 nmol (HPLC) RAP1GAP2 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)

Specifications

Condizioni di conservazione di stoccaggio

Store at -20°C

Spedito in

Ice chest + Ice pads

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Application Protocols

Item-specific, tested applications and recommended conditions are not provided for this SKU; refer to the supplier’s protocol sheet or CoA/Spec Sheet.

No further protocol details are available in the Product Data, and none are claimed here.

Biological Roles

Target overview (literature)

• RAP1GAP2 (Rap1 GTPase‑activating protein 2) is a GTPase‑activating protein that inactivates RAP1 by stimulating GTP hydrolysis. In platelets and other cells, RAP1 regulates integrin activation, secretion, and adhesion processes.
• RAP1GAP2 is localized to secretory granules/vesicles in platelets and participates in dense granule secretion and platelet activation signaling cascades via interactions with RAP1 effectors.

Research relevance of RAP1GAP2 knockdown (literature)

• Loss‑of‑function can help delineate RAP1‑dependent pathways in hemostasis‑related cell biology, vesicle trafficking, and GPCR‑mediated signaling.
• In non‑hematopoietic contexts, RAP1GAP family members modulate cell adhesion and polarity; RAP1GAP2‑specific roles may be explored via cell‑type‑specific knockdown.

siRNA mechanism (general)

• Duplex siRNA is processed by RISC; the antisense strand guides AGO2 to complementary RAP1GAP2 mRNA, promoting cleavage or translational repression and decreased protein levels.

Notes

• The above summarizes biological context from the literature. This SKU contains pre‑designed siRNAs intended for research on the human RAP1GAP2 gene; it is not for diagnostic or therapeutic use.

Buffer Applications

Item-specific details

• Supplied buffer/composition: Not specified for this item; refer to CoA/Spec Sheet.

General buffer guidance for siRNA (literature)

• Reconstitution: Use nuclease‑free water or TE buffer (10 mM Tris‑HCl, 1 mM EDTA, pH 7.5–8.0). TE can enhance stability during frozen storage.
• Working solutions: Prepare aliquots at 10–50 µM in RNase‑free water to minimize freeze–thaw cycles. Store aliquots at −20 °C.
• Annealing buffer (if single strands are supplied; not specified for this item): 10 mM Tris‑HCl, 50–100 mM NaCl, pH 7.5–8.0; heat to 90 °C for 1–2 min and cool slowly to form duplexes (procedure varies; check supplier guidance).
• Transfection complexation: Many lipid reagents recommend serum‑free, reduced‑salt media (e.g., Opti‑MEM) for complex formation, then addition to complete media.
• RNase control: Add RNase inhibitor only if compatible with downstream biology; maintain buffers free of divalent cations that may promote nuclease activity.

pH considerations

• Slightly basic pH (7.5–8.0) minimizes acid‑catalyzed RNA hydrolysis. Avoid prolonged exposure to pH <7 and elevated temperatures.

All specific buffer recipes for this SKU are not provided; defer to the CoA/Spec Sheet and your transfection reagent instructions.

Green Alternatives

Assessment

• siRNA workflows are predominantly aqueous and can align well with green chemistry principles by minimizing hazardous solvents and reagents.

Opportunities (general)

• Aqueous buffers: Favor nuclease‑free water or TE buffer over organic co‑solvents.
• Minimize plastic: Use reusable RNase‑decontaminated racks and reduce single‑use plastics where biosafety permits.
• Transfection reagents: Consider lower‑toxicity, biodegradable or peptide‑based delivery systems when compatible with experimental needs, as alternatives to some cationic lipids/polymers.
• Energy use: Store consolidated aliquots at −20 °C (as specified for this item) rather than −80 °C when stability permits.

Trade‑offs

• High‑efficiency delivery systems may increase cytotoxicity or waste; greener alternatives can reduce hazard but sometimes at the cost of transfection efficiency.

Comparison (general, literature)

• Conventional cationic lipid delivery: High efficiency; potential cytotoxicity and waste solvents during preparation.
• Polymer/peptide formulations: Often milder and more biodegradable; may require optimization for each cell type.

Item-specific environmental certifications or greener formulation details are not provided for this SKU.

Pharmaceutical Uses

Not typically applicable to this research reagent.

• This product is supplied for laboratory research use only. It is not intended for use as a drug substance, drug product, or excipient, and there is no pharmacopeial status indicated for this SKU.
• Any formulation or manufacturing use in regulated settings would require item‑specific quality documentation (e.g., GMP, residual solvent testing, endotoxin limits), which are not specified for this item.

Physical Properties

Item-specific properties

• Molecular weight, molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance/concentration/formulation: Not specified for this item; refer to CoA/Spec Sheet.
• Extinction coefficient, A260 conversion: Not specified for this item; refer to CoA/Spec Sheet.

General properties for siRNA (literature)

• Physical state: Typically supplied lyophilized or in aqueous, nuclease‑free buffer; highly water‑soluble.
• UV absorbance: Strong absorption at 260 nm; A260 is widely used to quantify RNA. Duplex formation slightly alters hyperchromicity relative to single strands.
• Stability: siRNA duplexes are susceptible to hydrolysis and RNase degradation; stability is enhanced at low temperature (≤ −20 °C) and in RNase‑free, slightly basic buffers (e.g., TE, pH ~7.5–8.0).
• pKa/logP: Not meaningful in the classical small‑molecule sense due to polyanionic, macromolecular character.
• Melting temperature (Tm): Sequence‑ and salt‑dependent; short duplexes typically exhibit Tm values in the 50–80 °C range under standard buffer/salt conditions (literature, varies widely).

Handling implications

• Avoid repeated freeze–thaw cycles to preserve duplex integrity.
• Work in RNase‑free conditions; use certified RNase‑free plasticware and reagents.

All exact numeric specifications, if required, should be taken from the item’s CoA/Spec Sheet.

Quality and Grades

Item-specific information

• Grade/purity, purification method, sequence verification: Not specified for this item; refer to CoA/Spec Sheet.

General context for siRNA quality (literature/industry practice)

• Purification levels: Desalted, cartridge‑purified, HPLC‑purified, or PAGE‑purified. HPLC/PAGE typically reduce truncated species and improve knockdown consistency, particularly for longer or modified strands.
• Identity confirmation: MALDI‑TOF/ESI‑MS for strand mass; analytical HPLC for purity; duplex annealing verification by native PAGE or melting analysis. Sequence is commonly verified by mass and synthesis report.
• Endotoxin/RNase: For cell‑based work, low endotoxin and RNase‑free status are critical. Vendors may report endotoxin units (EU/mg) and nuclease testing; this item provides no such specifications.
• Modifications: Chemical stabilization (e.g., 2′‑O‑Me, 2′‑F, PS linkages) can enhance serum stability and reduce immunostimulation. Presence/absence of modifications for this item is not specified.
• Set design: “Pre‑designed Set A” typically indicates multiple independent siRNA duplexes to the same human RAP1GAP2 target for screening and pooled use; exact count/sequence not specified.

Interpretation

• In the absence of explicit grade or purity metrics for this SKU, treat it as a research‑use siRNA set and verify suitability with a small‑scale pilot in the intended cell system. For regulatory or QC‑sensitive applications, request the product CoA/Spec Sheet.

Reaction and Applications

Context

• This product is a pre‑designed siRNA set targeting human RAP1GAP2, intended for RNA interference (RNAi) experiments in research settings.

Applications (literature/general)

• Gene knockdown: Transient silencing of RAP1GAP2 mRNA in human cell lines or primary cells to study RAP1GTPase signaling, platelet‑related pathways, and vesicle/secretory functions where RAP1GAP2 is implicated.
• Mechanistic studies: Dissecting roles of RAP1GAP2 in integrin activation, dense granule secretion, or cytoskeletal dynamics via loss‑of‑function approaches.
• Pooled versus individual duplexes: Using multiple duplexes concurrently can enhance knockdown and mitigate off‑target effects; testing individually supports target‑specific attribution of phenotypes.
• Validation workflows: Time‑course mRNA/protein quantification (qRT‑PCR, Western blot) to confirm degree and duration of knockdown; rescue with siRNA‑resistant RAP1GAP2 cDNA as a specificity control.

Practical tips (general)

• Optimize transfection: Start with a standard dose (e.g., 5–50 nM final siRNA, reagent‑dependent; literature) and titrate. Monitor cytotoxicity of the transfection reagent independently of siRNA.
• Controls: Include non‑targeting siRNA, positive control knockdown, and, where feasible, multiple independent RAP1GAP2 siRNAs.
• Assay window: Peak knockdown is often observed 24–72 h post‑transfection at the mRNA level and later at the protein/functional level.

Note: No application performance data are provided for this SKU; recommendations above are general RNAi practices.

Reaction Conditions

Not applicable.

• This SKU is an siRNA reagent used for biological knockdown and is not employed in classical chemical reactions. There are no temperatures, catalysts, or yields to report.
• For cell‑based delivery, consult your chosen transfection reagent’s protocol; item‑specific transfection conditions are not provided for this product.

Safety and Handling

Item-specific safety

• GHS classification, signal word, hazard statements, pictograms: Not specified for this item; refer to SDS.
• Research use note: For research use only.

General guidance for siRNA oligonucleotides (literature/best practice)

• Expected hazards: Synthetic nucleic acid duplexes are generally considered low hazard; however, solutions may contain trace salts or residual solvents depending on formulation. Always consult the SDS for authoritative information.
• PPE: Use lab coat, gloves (nitrile), and safety glasses. Change gloves frequently when working RNase‑free.
• Engineering controls: Handle in a clean area; a biological safety cabinet is recommended when preparing transfection mixes for cell culture to maintain sterility.
• Incompatibilities: Avoid RNases (ubiquitous on skin and in the environment). Do not mix with strong oxidants or acids/bases that could hydrolyze RNA.
• First aid (general): If contacted with skin/eyes, rinse with water. If inhaled (aerosols from lyophilized solids), move to fresh air. If ingested, rinse mouth with water. Seek medical attention as appropriate.
• Special risks: None specific are known for unmodified siRNA; cationic transfection reagents used alongside may pose additional hazards—consult their SDS.

Waste disposal

• Dispose of nucleic‑acid waste according to institutional biosafety procedures. Decontaminate surfaces with RNase‑degrading solutions or freshly prepared 0.1% DEPC‑free bleach as permitted by local policy.

Solvent Selection

Applicability

• As a nucleic acid reagent, this product is reconstituted in aqueous, RNase‑free media rather than organic solvents.

Recommended solvents/buffers (general guidance; not item‑specific)

• RNase‑free water (nuclease‑free, DEPC‑treated or equivalent): Suitable for short‑term stocks and immediate transfection use.
• TE buffer (10 mM Tris‑HCl, 1 mM EDTA, pH 7.5–8.0): Common for long‑term storage to minimize hydrolysis and metal‑catalyzed degradation.
• siRNA resuspension/annealing buffers: Often 10 mM Tris or HEPES with 50–100 mM NaCl or KCl; exact composition varies by protocol and is not specified for this item.

Miscibility and compatibility (literature)

• Fully miscible with aqueous buffers; avoid organic solvents that denature RNA or interfere with transfection (e.g., phenol, alcohols at high %).
• When complexing with transfection reagents, follow the reagent vendor’s buffer requirements (often serum‑free media like Opti‑MEM during complex formation).

Selection notes

• Use water for immediate use and TE for freezer stocks. Avoid divalent cations (Mg2+, Ca2+) unless required by a specific protocol, as they can promote RNase activity.
• Filter sterilize buffers (0.22 µm) and prepare with RNase‑free technique.

Item-specific solvent guidance is not provided; defer to the CoA/Spec Sheet if included.

Storage and Reconstitution

Item-specific instructions (from Product Data)

• Storage: Store at −20 °C.
• Shipping: Shipped in an ice chest with ice pads.
• Reconstitution: Not specified for this item; refer to CoA/Spec Sheet.

General notes (context)

• To maximize stability, store siRNA in RNase‑free conditions, protected from repeated freeze–thaw. If reconstitution guidance is provided separately, prepare small aliquots for single use.

Only the storage temperature and shipping conditions above are specified for this SKU; all other details should be confirmed from the product documentation.

Structure and Identity

Item-specific facts (from Product Data)

• SKU: R1488059
• Product name: RAP1GAP2 Human Pre-designed siRNA Set A
• Intended target: RAP1GAP2 gene (Homo sapiens)
• CAS, CID, InChIKey, SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula and molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

General description (literature)

• Composition: A pre-designed siRNA “set” typically comprises multiple double‑stranded RNA duplexes (commonly 19–27 base pairs with 2‑nt 3′ overhangs) directed against distinct regions of the same transcript to improve knockdown robustness and reduce off‑target risk.
• Structural features: Each siRNA consists of two antiparallel RNA strands (sense and antisense). Typical features include 3′‑UU or TT overhangs, 5′‑phosphate termini (may be present or introduced intracellularly), and optional chemical stabilizations (e.g., 2′‑O‑Me, 2′‑F, phosphorothioate) depending on supplier. Specific modifications for this item are not provided.
• 2D structure (conceptual): Two short RNA strands (ribose–phosphate backbone with canonical A, U, G, C bases) annealed to form a duplex with Watson–Crick base pairing; antisense strand is complementary to the RAP1GAP2 mRNA target sequence.

Notes

• Any exact sequence(s), length, strand orientation, and chemical modifications for this item are not specified; consult the product CoA/Spec Sheet if available.

Synthetic Utility

Scope

• As a functional genomics reagent, siRNA is not a small‑molecule synthetic building block. Its “utility” lies in enabling target validation and pathway dissection that inform subsequent chemical biology and medicinal chemistry efforts.

Use in research workflows (general)

• Target validation: Knockdown of RAP1GAP2 to confirm phenotypic linkage before investing in small‑molecule inhibitor discovery.
• Pathway mapping: Combining RAP1GAP2 siRNA with pharmacological modulators of RAP1 signaling to define epistatic relationships.
• Screening: Pooled siRNA sets can be used in pilot screens to identify assay responsiveness and dynamic range.

Chemistry interface

• siRNA perturbations help interpret SAR by correlating chemical probe phenotypes with genetic suppression of RAP1GAP2. Convergent effects strengthen on‑target hypotheses.

Note

• No chemical synthesis conditions or transformations are relevant for this item.

Target Specificity

Item-specific information (from Product Data only)

• Target gene: RAP1GAP2 (Human)
• Product type: Pre‑designed siRNA Set A (multiple siRNA duplexes; exact count and sequences not specified)
• Clone/isotype/epitope/species cross‑reactivity: Not applicable to siRNA; not specified for this item.

Notes

• Sequence details, target exon regions, and predicted off‑target analysis are not provided for this SKU; refer to the CoA/Spec Sheet if available.